Table 4 Comparison of 2-year outcomes between MAC and RIC haplo-SCT according to disease status

Diagnosis

AML

36.1 % (31.6–40.6)

31.6 % (27.4–35.9)

32.2 % (27.7–36.7)

37.7 % (33.1–42.4)

29.2 % (24.8–33.7)

ALL

40 % (32.5–47.3)

32.9 % (28.6–37.2)

27.2 % (20.2–34.1)

33.3 % (25.9–40.7)

29.8 % (22.8–37.2)

p

0.43

0.87

0.45

0.40

0.67

All patients

 CR1

RIC

30.1 % (19.1–41.9)

31.1 % (24.1–38.3)

38.9 % (26.4–51.3)

46.9 % (34.1–59.8)

26 % (15–38.3)

MAC

21.5 % (15.4–28.3)

29.1 % (22.2–36.3)

49.1 % (41.2–57.1)

55.4 % (47.5–63.4)

41 % (32.8–48.9)

p

0.21

0.80

0.42

0.64

0.10

  ≥ CR2

RIC

38.5 % (25.8–51.1)

36.8 % (28.2–45.5)

24.6 % (13.1–36.1)

29.8 % (17.7–41.9)

29.6 % (17.5–42.8)

MAC

30 % (21.5–39)

27.8 % (19.7–36.4)

42.2 % (32.6–51.7)

47.7 % (38–57.5)

37 % (27.4–46.6)

p

0.38

0.25

0.06

0.07

0.53

 Active dis.

RIC

55.8 % (45.9–64.6)

32.9 % (24.5–41.5)

11.3 % (5–17.5)

14.3 % (7.3–21.3)

21.4 % (13.8–30.1)

MAC

51.9 % (42.3–60.6)

37.1 % (28.6–45.7)

11 % (4.7–17.2)

18.5 % (11.2–25.7)

15.2 % (9.2–22.7)

P

0.52

0.38

0.64

0.60

0.29